Literature DB >> 27900477

The influence of seasonality and manufacturer kit lot changes on 17α-hydroxyprogesterone measurements and referral rates of congenital adrenal hyperplasia in newborns.

Melissa Pearce1, Erin Dauerer2, A Gregory DiRienzo2, Michele Caggana1, Norma P Tavakoli3,4.   

Abstract

Newborn screening for congenital adrenal hyperplasia (CAH) is performed by measuring the concentration of 17α-hydroxyprogesterone (17-OHP) in dried blood spots. Unfortunately, the level of 17-OHP varies due to multiple factors, and therefore, the false positive rate for the test is a challenge. We analyzed screening data from 2007 to 2015 to determine the effect of seasonal changes and manufacturer kit lot changes on 17-OHP values and on numbers of infants referred. Data from screening 2.2 million infants over a 9-year period indicates that in the NYS during the colder months, daily mean 17-OHP values are higher, more retests are performed, and more infants are referred even though fewer infants are born. The practice of using fixed cutoffs for referring infants for CAH leads to more false positive results in colder months. In addition, there was an overall 10% increase in the daily mean 17-OHP values from the 2 years before and after a manufacturer kit lot change that occurred in November 2013, suggestive of a functional change in the kit at that time.
CONCLUSION: Newborn screening programs should be cognizant of seasonal temperature variations and (un)anticipated manufacturer kit changes because they may affect 17-OHP values and CAH referral rates. What is Known: • Newborn screening for congenital adrenal hyperplasia is generally performed by measuring 17α-hydroxyprogesterone (17-OHP) levels in dried blood spots. • 17-OHP concentrations are affected by gestational age/weight of infant when specimen is collected, specimen collection time after birth, as well as race and sex of infant. What is New: • Seasonal temperature variations and unanticipated manufacturer kit changes affect 17-OHP levels and consequently referral rates in programs that use fixed cutoffs. • Daily mean 17-OHP is generally higher when the ambient temperature is lower.

Entities:  

Keywords:  17α-Hydroxyprogesterone; Congenital adrenal hyperplasia; Newborn screening; Positive predictive value; Seasonal variation

Mesh:

Substances:

Year:  2016        PMID: 27900477     DOI: 10.1007/s00431-016-2814-7

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  27 in total

1.  Stability of 17alpha-hydroxyprogesterone in dried blood spots after autoclaving and prolonged storage.

Authors:  Dóra Török; Adolf Mühl; Felix Votava; Georg Heinze; János Sólyom; Julia Crone; Sylvia Stöckler-Ipsiroglu; Franz Waldhauser
Journal:  Clin Chem       Date:  2002-02       Impact factor: 8.327

2.  Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value.

Authors:  Bernhard Olgemöller; Adelbert A Roscher; Bernhard Liebl; Ralph Fingerhut
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

3.  Newborn screening for congenital adrenal hyperplasia in New Zealand, 1994-2013.

Authors:  Natasha L Heather; Sumudu N Seneviratne; Dianne Webster; José G B Derraik; Craig Jefferies; Joan Carll; Yannan Jiang; Wayne S Cutfield; Paul L Hofman
Journal:  J Clin Endocrinol Metab       Date:  2014-12-12       Impact factor: 5.958

4.  Assessment of corpus luteum function by direct radioimmunoassay for progesterone in blood spotted on filter paper.

Authors:  P Petsos; W A Ratcliffe; D C Anderson
Journal:  Clin Chem       Date:  1985-08       Impact factor: 8.327

5.  Plasma 17-hydroxyprogesterone concentrations in ill newborn infants.

Authors:  J F Murphy; B G Joyce; J Dyas; I A Hughes
Journal:  Arch Dis Child       Date:  1983-07       Impact factor: 3.791

6.  Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia.

Authors:  B L Therrell; S A Berenbaum; V Manter-Kapanke; J Simmank; K Korman; L Prentice; J Gonzalez; S Gunn
Journal:  Pediatrics       Date:  1998-04       Impact factor: 7.124

7.  Newborn screening for congenital adrenal hyperplasia in Cuba: six years of experience.

Authors:  Ernesto Carlos González; Frank Carvajal; Amarilys Frómeta; Ana Luisa Arteaga; Elisa María Castells; Tania Espinosa; Remigio Coto; Pedro Lucio Pérez; Yileidis Tejeda; Lesley Del Río; Mary Triny Segura; Pedro Almenares; René Robaina; José Luis Fernández
Journal:  Clin Chim Acta       Date:  2013-02-26       Impact factor: 3.786

Review 8.  Neonatal screening for congenital adrenal hyperplasia.

Authors:  Perrin C White
Journal:  Nat Rev Endocrinol       Date:  2009-09       Impact factor: 43.330

9.  Direct solid-phase radioimmunoassay for screening 17 alpha-hydroxyprogesterone in whole-blood samples from newborns.

Authors:  L F Hofman; J E Klaniecki; E K Smith
Journal:  Clin Chem       Date:  1985-07       Impact factor: 8.327

10.  Results from 28 years of newborn screening for congenital adrenal hyperplasia in sapporo.

Authors:  Shuntaro Morikawa; Akie Nakamura; Kaori Fujikura; Masaru Fukushi; Tomoyuki Hotsubo; Jun Miyata; Katsura Ishizu; Toshihiro Tajima
Journal:  Clin Pediatr Endocrinol       Date:  2014-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.